drugset / Trial / NCT00097812

Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid

NCT00097812

Phase 3 Completed 220 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.

Timeline

Start
2004-05
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified

Indications